Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Anthony M. Hunter, MD, Nelson Ryan, PharmD, Mohammad Hussaini, MD, Ratilal Akabari, Alan F. List, MD, Jeffrey Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Javier Pinilla Ibarz, MD PhD, Andrew T Kuykendall, MD, Ling Zhang, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4167.

https://doi.org/10.1182/blood-2019-130196

Published: 2019

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Hamza Hashmi, MD, Jeffrey Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Lia Perez, MD, Farhad Khimani, MD, Michael Nieder, MD, Hany Elmariah, MD MS, Joseph Pidala, MD, Nelli Bejanyan, MD, Alan F. List, MD, Claudio Anasetti, MD, Taiga Nishihori, MD

Blood (2019) 134 (Supplement_1): 5739.

https://doi.org/10.1182/blood-2019-128985

Published: 2019

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)

Mikkael A. Sekeres, MD, MS, Holly Gundacker, Jeffrey Lancet, MD, Anjali Advani, MD, Stephen Petersdorf, Jane L. Liesveld, MD, Deborah Mulford, Tom Norwood, Cheryl L. Willman, MD, Alan F. List, Frederick R. Appelbaum, MD

Blood (2010) 116 (21): 332.

https://doi.org/10.1182/blood.V116.21.332.332

Published: 2010

Journal Articles

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

Maria Corrales-Yepez, MD, Mohamed A. Kharfan-Dabaja, MD, Jeffrey Lancet, MD, Alan F. List, MD, Eric Padron, MD, Dana Rollison, PhD, P.K. Epling-Burnette, PharmD, PhD, Ling Zhang, MD, Teressa Field, MD, Javier Pinilla-Ibarz, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 4001.

https://doi.org/10.1182/blood.V116.21.4001.4001

Published: 2010

Journal Articles

Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Transformation From Essential Thrombocythemia (ET) In Patients Treated with Hydroxyurea or Anagrelide: A Single Center Series of 17 Cases

Jeremy W Bowers, MD, Jijun Liu, MD, Kenneth S. Zuckerman, MD, Mojdeh Naghashpour, MD, PhD, Jeffrey Lancet, MD, Rami S. Komrokji, MD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2010) 116 (21): 4102.

https://doi.org/10.1182/blood.V116.21.4102.4102

Published: 2010

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Eric J. Feldman, MD, Jeffrey Lancet, MD, Jonathan E. Kolitz, MD, Ellen Ritchie, MD, Alan F. List, MD, Ekatherine Asatiani, MD, Tania J Curcio, Michelle Burton, RN, Marge Fricano, BSN, Christine Swenson, Lawrence D Mayer, PhD, Arthur C. Louie, MD

Blood (2008) 112 (11): 2984.

https://doi.org/10.1182/blood.V112.11.2984.2984

Published: 2008

Journal Articles

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Farhad Ravandi, MBBS, Deepa Sampath, PhD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Srdan Verstovsek, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Vernon Alvarez, PhD, Michael D Becker, Alan F. List, MD, Said Sebti, PhD, Hagop M. Kantarjian, MD, Jeffrey Lancet, MD

Blood (2008) 112 (11): 2987.

https://doi.org/10.1182/blood.V112.11.2987.2987

Published: 2008

Journal Articles

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia.

Jeffrey Lancet, MD, Judith E. Karp, MD, Larry D. Cripe, MD, Gail J. Roboz, MD, Matt Suster, Nguyen Tan, Rachael Hawtin, Judith Fox, Craig Berman, Glenn Michelson

Blood (2008) 112 (11): 1955.

https://doi.org/10.1182/blood.V112.11.1955.1955

Published: 2008

Journal Articles

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Jeffrey Lancet, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Sem Bastien, R.N., Katrina Alino, R.N., Glenn Michelson, M.D., Judith Karp, M.D.

Blood (2007) 110 (11): 442.

https://doi.org/10.1182/blood.V110.11.442.442

Published: 2007

Journal Articles

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Farhad Ravandi, MD, Jeffrey Lancet, MD, Francis Giles, MD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Stefan Faderl, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Lawrence Akinsanmi, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 913.

https://doi.org/10.1182/blood.V110.11.913.913

Published: 2007

Journal Articles

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Jeffrey Lancet, MD, Maria R. Baer, MD, Ivana Gojo, MD, M. Burton, M. Quinn, S.M. Tighe, Kapil Bhalla, MD, K. Kersey, S. Wells, Z. Zhong, PhD, B. Sadler, Maher Albitar, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS

Blood (2006) 108 (11): 1961.

https://doi.org/10.1182/blood.V108.11.1961.1961

Published: 2006

NARROW

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Transformation From Essential Thrombocythemia (ET) In Patients Treated with Hydroxyurea or Anagrelide: A Single Center Series of 17 Cases

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia.

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only